Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26225352 | 0.79 | — | — | |
| SCHEMBL24196686 | 0.79 | — | — | |
| SCHEMBL120101 | 0.75 | TSHR (0.39) | — | |
| SCHEMBL27515089 | 0.75 | — | — | |
| SCHEMBL25817290 | 0.75 | CYP1A2 (0.34) | — | |
| SCHEMBL20146547 | 0.75 | — | — | |
| SCHEMBL8917677 | 0.73 | RAPGEF4 (0.39) | — | |
| SCHEMBL10068236 | 0.73 | TTR (0.48) | TTR | |
| SCHEMBL23268459 | 0.73 | — | — | |
| SCHEMBL19851280 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228513-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2024-07-11 | — | — | US | disclosed |
| CN-103570620-B | The luxuriant and rich with fragrance compounds of a kind of 1,12-imino group benzo [c], intermediate and preparation method and application | 昆山维信诺显示技术有限公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-103570620-A | 1,12-iminobenzo[c]phenanthrene compound, intermediate, preparation method and application of compound | KUNSHAN VISIONOX DISPLAY TECH | 2014-02-12 | — | — | CN | disclosed |
| US-20100001635-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-01-07 | — | — | US | disclosed |
| EP-2108690-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090153039-A1 | Green electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-06-18 | — | — | US | disclosed |
| EP-2067766-A1 | Green electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-06-10 | — | — | EP | disclosed |
| CN-101301294-A | Combinated inhibitors of FBP-ase and antidiabetic agents for diabetes treatment | METABEHJSIS TERAP JUTIKS INK (US) | 2008-11-12 | — | — | CN | disclosed |
| CN-1516705-A | Novel arylfructose-1, 6-bisphosphatase inhibitors | ֢�����ƹ�˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-0655434-B1 | Aromatic diamine compounds useful for electroluminescence device | NISSHIN SPINNING (JP) | 1996-09-25 | — | — | EP | disclosed |
| EP-0655434-A1 | Aromatic diamine compounds useful for electroluminescence device | NISSHINBO INDUSTRIES, INC. (JP) | 1995-05-31 | — | — | EP | disclosed |
| US-5420351-A | Charge transport compounds for electrography | NISSHINBO INDUSTRIES, INC. (JP) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | TTR 840/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | TTR 840/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | TTR 1772/4885 |
| US-20100001635-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, ILF2, L1CAM | TTR 3939/4885 |
| US-20240228513-A1 | ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES | OR10J3, ORC3, C1R | TTR 948/4885 |
| US-20090153039-A1 | Green electroluminescent compounds and organic electroluminescent device using the same | C1S, ACSL3, CCNL2 | TTR 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.